ASCO: GLP-1 Receptor Agonists May Reduce Risk for Obesity-Related Cancer, All-Cause Death
WEDNESDAY, May 28, 2025 -- For adults with diabetes and obesity, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with a reduced risk for obesity-related cancer compared with dipeptidyl peptidase-4 (DPP-4) inhibitors, according to a study scheduled to be presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago.
Noting that obesity is a risk factor for cancer development, Lucas Mavromatis, from the NYU Grossman School of Medicine in New York City, and colleagues examined whether GLP-1 RAs reduce the risk for obesity-related cancer in adults with diabetes and obesity compared to weight-neutral DPP-4 inhibitors. Data were included for 85,015 adults with a body mass index ≥30 kg/m2 and a diagnosis of diabetes who newly initiated a GLP-1 RA or DPP-4 inhibitor between 2013 and 2023. Patients prescribed GLP-1 RAs were matched 1:1 on propensity score with those prescribed DPP-4 inhibitors.
The researchers found that the risks for obesity-related cancers and all-cause death were lower during a mean follow-up of 3.9 years (adjusted hazard ratios, 0.93 and 0.92, respectively) in association with GLP-1 RA versus DPP-4 inhibitor use. Protective associations were seen between GLP-1 RA use and colon and rectal cancers.
"Our results suggest [GLP-1 RAs] may modestly cut the chance of developing certain cancers -- especially cancers of the colon and rectum -- and reduce rates of death due to all causes," Mavromatis said in a statement. "These data are reassuring, but more studies are required to prove causation."
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
GLP-1 RAs Cost-Effective Versus Usual Care for Knee OA, Obesity
WEDNESDAY, Sept. 17, 2025 -- Compared with usual care, the glucagon-like peptide 1 receptor agonists (GLP-1 RAs) tirzepatide and semaglutide are cost-effective for people with...
Without Biannual Time Shift, Prevalence of Obesity, Stroke May Be Reduced
WEDNESDAY, Sept. 17, 2025 -- The prevalence of obesity and stroke would be reduced with permanent Standard Time (SDT) and Daylight Saving Time (DST) compared with the current...
Weight-Loss Surgery Bests Medical Weight Management for Obesity-Related Risk Mitigation
WEDNESDAY, Sept. 17, 2025 -- Bariatric surgery is associated with a significantly lower risk for developing major metabolic comorbidities compared with a medical weight management...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.